Literature DB >> 15983898

Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis.

Holly M Scott Algood1, Philana Ling Lin, JoAnne L Flynn.   

Abstract

Inflammatory cells migrate to the lungs in response to Mycobacterium tuberculosis infection. These infiltrating cells organize into a structure called a granuloma, which controls and contains infection. The signals that influence the formation of granulomas are largely unknown. Tumor necrosis factor (TNF) has been demonstrated to be required for formation of granulomas, in mouse models of tuberculosis, and for control of latent tuberculosis, in humans. We investigated the mechanisms by which TNF controls cell migration in response to M. tuberculosis infection, focusing on the effects of this cytokine on chemokine expression. Chemokines are small molecules that direct the migration of cells within the body. Our data support the notion that TNF is required for appropriate chemokine expression by M. tuberculosis-infected macrophages, both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983898     DOI: 10.1086/429994

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  96 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  The roles of microRNAs on tuberculosis infection: meaning or myth?

Authors:  Harapan Harapan; Fitra Fitra; Ichsan Ichsan; Mulyadi Mulyadi; Paolo Miotto; Nabeeh A Hasan; Marta Calado; Daniela M Cirillo
Journal:  Tuberculosis (Edinb)       Date:  2013-08-15       Impact factor: 3.131

3.  Inflammatory and Anti-inflammatory Responses Co-exist Inside Lung Granuloma of Fatal Cases of Coccidioidomycosis: A Pilot Report.

Authors:  Heidi G Rodriguez-Ramirez; Adolfo Soto-Dominguez; Gloria M González; Oralia Barboza-Quintana; Mario C Salinas-Carmona; Luis A Ceceñas-Falcon; Roberto Montes-de-Oca-Luna; Alma Y Arce-Mendoza; Adrian G Rosas-Taraco
Journal:  Mycopathologia       Date:  2018-05-07       Impact factor: 2.574

4.  Lactoferrin modulation of mycobacterial cord factor trehalose 6-6'-dimycolate induced granulomatous response.

Authors:  Kerry J Welsh; Shen-An Hwang; Robert L Hunter; Marian L Kruzel; Jeffrey K Actor
Journal:  Transl Res       Date:  2010-06-30       Impact factor: 7.012

5.  Lack of alpha-1 integrin alters lesion morphology during pulmonary Mycobacterium tuberculosis infection.

Authors:  Jennifer L Taylor; Helle Bielefeldt-Ohmann; Ambra Pozzi; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2008-07-18       Impact factor: 3.131

6.  Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death.

Authors:  Hilary Clay; Hannah E Volkman; Lalita Ramakrishnan
Journal:  Immunity       Date:  2008-08-15       Impact factor: 31.745

7.  Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Authors:  Yesim Ozguler; Gulen Hatemi; Serdal Ugurlu; Emire Seyahi; Melike Melikoglu; Sermin Borekci; Ersan Atahan; Gul Ongen; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2016-10-03       Impact factor: 2.631

8.  Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis.

Authors:  Wen-Lin Su; Wann-Cherng Perng; Ching-Hui Huang; Cheng-Yu Yang; Chin-Pyng Wu; Jenn-Han Chen
Journal:  Clin Vaccine Immunol       Date:  2009-12-09

Review 9.  The role of dendritic cells in mycobacterium-induced granulomas.

Authors:  Heidi A Schreiber; Matyas Sandor
Journal:  Immunol Lett       Date:  2010-01-04       Impact factor: 3.685

Review 10.  Tumor necrosis factor inhibitors and infection complications.

Authors:  Monica Crawford; Jeffrey R Curtis
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.